Epithalon Anti-Aging Research Protocol 2026: Khavinson Studies, Telomere Research & Reconstitution Guide

For research purposes only. Not for human consumption.

# Epithalon Anti-Aging Research Protocol 2026: Khavinson Studies, Telomere Research & Reconstitution Guide

Epithalon (also written Epitalon; IUPAC name: Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from Epithalamin, a naturally occurring polypeptide extract of the pineal gland. Developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, Epithalon has been studied in preclinical and limited clinical research contexts for its reported effects on telomere dynamics, telomerase activation, and markers of biological aging.

This research protocol guide provides the practical framework for researchers working with Epithalon: the scientific background from Khavinson's research program, reconstitution procedures, administration routes and dosing windows documented in published literature, storage conditions, and guidance for study design.

> Research Use Only Disclaimer: Epithalon is a research compound and is not approved by the FDA or any regulatory authority for human therapeutic use. All information in this guide is intended for licensed researchers and institutional settings only. This is not medical advice.

---

Historical Context: The Khavinson Research Program

Epithalon's development emerged from decades of research into peptide bioregulators — short peptides believed to modulate gene expression patterns associated with aging. Khavinson's group at the Institute of Bioregulation and Gerontology in St. Petersburg developed a systematic approach to studying how short oligopeptides derived from various tissues could modulate age-related physiological changes.

The Epithalamin program (from which Epithalon was later synthesized as a simplified tetrapeptide) began in the 1970s–1980s, and published research on the synthetic Epithalon compound accelerated through the 1990s and 2000s, with over 100 peer-reviewed papers published from Khavinson's laboratory and collaborators.

The body of research on Epithalon from Khavinson's laboratory and collaborators examines several mechanisms of potential relevance to aging (PMID: 42021992, 40141333). Key themes in the Epithalon research program include:

1. Telomere maintenance — Effects on telomere length and telomerase enzyme activity

2. Circadian rhythm modulation — Pineal-derived peptides and melatonin regulation

3. Gene expression — Effects on markers of cellular senescence including PCNA (Proliferating Cell Nuclear Antigen) and p53

4. Lifespan extension in animal models — Increased mean and maximum lifespan in rodent studies

5. Oncostatic effects — Reduction in spontaneous tumor formation in long-term rodent studies

---

Mechanism of Action: How Epithalon Is Studied

Telomerase Activation

The most frequently cited mechanism studied in Epithalon research is activation of telomerase reverse transcriptase (TERT) — the catalytic component of the enzyme that extends telomeres. In cells that have exited the cell cycle and silenced TERT expression (a characteristic of somatic cell aging), Epithalon has been reported to partially restore telomerase activity. (PMID: 40908429)

PCNA and Cell Cycle Regulation

PCNA (Proliferating Cell Nuclear Antigen) serves as a molecular marker of active DNA replication and cell cycle progression. Epithalon research has examined its effects on PCNA expression in aging and cancer model systems, with some studies reporting restoration of PCNA levels in aged tissue to levels more characteristic of younger animals.

Gene Expression and Epigenetics

Research from Khavinson's group and other laboratories has examined the gene expression effects of Epithalon (PMID: 16705247). Research from Khavinson's group proposes that Epithalon's tetrapeptide structure allows it to interact with histone proteins and modulate chromatin accessibility at specific gene promoters. Studies using gel-shift assays and gene reporter systems have examined whether Epithalon affects expression of longevity-associated genes including telomerase reverse transcriptase, thioredoxin, and defensin.

Melatonin and Pineal Function

As a pineal-derived peptide analog, Epithalon has been examined for its relationship with melatonin secretion. Several studies report that Epithalon treatment in aged animals is associated with restored nocturnal melatonin amplitude — a pattern that typically declines with age in both rodents and humans.

---

Epithalon Research Protocol: Reconstitution Guide

Materials Required

• •Lyophilized Epithalon vial (typically 10 mg, 20 mg, or 50 mg)
• •Bacteriostatic water or sterile saline (0.9% NaCl)
• •Insulin syringes (1 mL, 27–31 gauge) for injection models
• •Pipettes and sterile culture medium for in vitro studies
• •Amber vials or light-protected storage containers

Target Concentrations for Research

For in vivo injection studies:

• •1 mg/mL — add 10 mL to a 10 mg vial (standard for subcutaneous protocols)
• •2 mg/mL — add 5 mL to a 10 mg vial (higher concentration for smaller injection volumes)

For in vitro cell culture studies:

• •Stock solution: 1 mg/mL in sterile water or PBS
• •Working concentrations: 0.1–100 ng/mL in culture medium (from serial dilutions of stock)

Dissolution Procedure

Epithalon is a water-soluble tetrapeptide that dissolves readily in aqueous solvents. Unlike some longer peptides, reconstitution of Epithalon is generally straightforward:

1. Allow the sealed lyophilized vial to reach room temperature (15–20 minutes) to reduce condensation during opening.

2. Clean the rubber stopper with an alcohol swab; allow to air dry 60 seconds.

3. Draw the calculated solvent volume into a syringe.

4. Insert needle at 45° angle; direct solvent stream to the vial wall, not the powder directly.

5. Roll gently — Epithalon typically dissolves within 30–60 seconds given its small molecular size (MW: 390.3 g/mol).

6. Inspect: solution should be clear and colorless. Discard if turbid or colored.

Quality Checks Before Use

• •Color: Clear, colorless solution. Yellow or brown discoloration indicates degradation.
• •Clarity: No visible particulates. If solution is cloudy, filter through 0.22 µm sterile filter or discard.
• •pH: Epithalon solutions are typically pH 5–7. Gross deviation may indicate contamination.
• •Timing: Do not use reconstituted Epithalon beyond its stated stability window.

---

Administration Routes in Epithalon Research

Subcutaneous Injection (Most Common)

The majority of Khavinson's published in vivo research employed subcutaneous injection as the primary administration route. This allows for:

• •Reliable systemic absorption in rodent models
• •Consistent dosing across study cohorts
• •Straightforward adaptation from clinical research protocols

In rodent longevity studies, injections were typically administered in cycles (e.g., twice daily for 5 consecutive days, repeated every 1–3 months) rather than continuous daily dosing.

Intranasal Administration

Some Epithalon research protocols have employed intranasal delivery, particularly for examining central nervous system and pineal-related outcomes. Intranasal delivery bypasses the blood-brain barrier through olfactory and trigeminal nerve pathways, which may be relevant given Epithalon's proposed central effects on pineal function.

Intranasal protocol considerations:

• •Typically formulated at higher concentrations (2–5 mg/mL) to compensate for partial absorption
• •Delivered in small volumes (5–10 µL per nostril) using micropipettes or specialized mucosal atomization devices
• •Timing relative to circadian phase may be relevant for pineal-related endpoints

Intraperitoneal Injection

IP injection has been used in some rodent studies for faster systemic distribution. This route may be appropriate for acute pharmacological studies where rapid peak concentration is required.

In Vitro Cell Culture

Cell culture research with Epithalon typically uses:

• •Serum-free or low-serum conditions during peptide exposure to minimize interaction with serum proteins
• •Concentrations of 0.01–100 ng/mL (far lower than typical in vivo doses due to direct cellular access)
• •Exposure periods of 24–72 hours for acute studies; repeated treatment protocols over multiple passages for senescence research

---

Dosing Windows and Timing in Published Research

Typical Dose Ranges in Preclinical Literature

Cyclic vs. Continuous Dosing

Khavinson's long-term rodent studies primarily used cyclic dosing protocols rather than continuous daily administration. The most commonly cited protocol in published literature is:

• •5 consecutive days of treatment
• •Followed by a rest period of 25–30 days
• •Repeated cycle throughout the study duration

This cyclic approach was used in lifespan studies in both rats and Drosophila melanogaster models, and was proposed to mimic a more physiological pulsatile exposure pattern.

Timing Relative to Light-Dark Cycle

For pineal-related and melatonin research endpoints, Epithalon injection timing relative to the circadian light-dark cycle may be relevant. Several studies administered Epithalon injections during the early dark phase (ZT12–14 in 12:12 LD cycle), which corresponds to the rising phase of nocturnal melatonin in rodents.

---

Key Epithalon Research Findings

Lifespan Extension Studies

Multiple studies by Anisimov, Khavinson, and colleagues examined whether Epithalon treatment in aging rodent models altered mean or maximum lifespan. Studies in NIO mice and Wistar rats reported:

• •Mean lifespan increases of 13–25% in some treatment cohorts compared to controls
• •Maximum lifespan extension of 10–16% in several studies
• •Reduced tumor incidence — particularly mammary tumors in female rodents, with incidence reductions of 30–50% in some cohorts

A study by Anisimov et al. published in Annals of the New York Academy of Sciences examined Epithalamin (the parent compound) alongside other peptide bioregulators and reported that pineal peptide preparations were among the most effective at extending lifespan in rodent models, with the greatest effects seen in animals with elevated baseline cancer risk.

Telomere Research

• •Increased telomere length measured by Southern blotting and FISH
• •Elevated telomerase activity by TRAP assay
• •Extended replicative lifespan compared to untreated controls

These findings have generated significant interest given that telomere shortening is established as a cellular correlate of aging, and telomerase activation is a marker of cellular rejuvenation in certain model systems.

Retinal and Visual System Research

A distinctive area of Epithalon research examines its effects on the aging retina. Studies in aging rats report restoration of photoreceptor morphology, preservation of electroretinogram amplitude, and reduced lipofuscin accumulation in retinal pigment epithelium of Epithalon-treated animals compared to controls.

Khavinson and colleagues have proposed that this reflects a broader "tissue-protective" action of pineal peptides on post-mitotic cells that cannot replace damaged components through cell division.

Circadian and Melatonin Studies

Studies in aged Wistar rats report that Epithalon treatment restored the amplitude of the nocturnal melatonin peak to levels approximating those seen in younger animals. Older animals typically show blunted nocturnal melatonin surges, and Epithalon's apparent ability to normalize this pattern may explain some of its proposed anti-aging actions through improved circadian regulation.

---

Vial Handling and Storage for Epithalon

Lyophilized Storage Conditions

Epithalon's tetrapeptide structure (Ala-Glu-Asp-Gly) is relatively stable compared to longer peptides, but it remains susceptible to:

• •Moisture absorption — oxidizes and aggregates with water exposure
• •Acidic or alkaline pH — Asp and Glu residues are pH-sensitive
• •UV light — photodegrades peptide bonds

Reconstituted Epithalon Storage

• •Store at 2–8°C for up to 28–30 days when reconstituted with bacteriostatic water
• •Keep in the dark; use amber vials where possible
• •For longer storage of in vitro aliquots, freeze at -20°C in small single-use volumes
• •Avoid repeated freeze-thaw cycles

Shipping and Cold Chain

Epithalon is typically shipped lyophilized at ambient temperature for short shipping periods (1–3 days), but should be refrigerated immediately upon receipt. For long-distance or international shipping, cold packs maintaining 2–8°C are preferred to maintain stability through transit.

---

Study Design Considerations for Epithalon Research

Endpoint Selection

Researchers planning Epithalon studies should align endpoints with the most clearly supported preclinical findings:

Telomere-related endpoints:

• •Telomere length (Southern blot, qPCR-based relative telomere length, or FISH)
• •Telomerase activity (TRAP assay)
• •TERT mRNA expression (RT-qPCR)

Cellular senescence endpoints:

• •Senescence-associated β-galactosidase (SA-β-gal) staining
• •p16/p21 expression
• •γ-H2AX foci (DNA damage marker)
• •Replicative lifespan (population doublings to senescence)

In vivo aging endpoints:

• •Melatonin rhythm (plasma sampling across light-dark cycle)
• •Tumor incidence in cancer-prone strains
• •Body weight trajectory and metabolic parameters
• •Survival analysis

Cell and Tissue Models

Epithalon's published research has used:

• •Human fetal fibroblasts (WI-38, IMR-90) — Classic telomere/senescence models
• •Rat primary cultures — Hippocampal, cortical, and retinal neurons for CNS studies
• •Drosophila melanogaster — Invertebrate longevity assays
• •C. elegans — Life extension model
• •Inbred rat and mouse strains — Long-term rodent survival studies

Controls and Blinding

Critical controls for Epithalon studies:

• •Vehicle control (identical volume of bacteriostatic water or saline)
• •Age-matched young vs. old comparisons where studying aging-reversal effects
• •Positive control where available (e.g., known telomerase activator for telomere assays)
• •Blinded outcome assessment — particularly important for histological and behavioral endpoints

---

Literature Gaps and Research Opportunities

What Is Not Known

The Epithalon research literature has notable limitations that represent opportunities for further investigation:

1. Mechanism specificity — The molecular target(s) of Epithalon remain incompletely characterized. Whether it directly binds to histones, telomere-associated proteins, or other cellular targets is not fully established.

2. Human pharmacokinetics — There is limited published data on Epithalon pharmacokinetics in humans, including absorption, distribution, and metabolic fate.

3. Dose-response characterization — Many published studies used only 1–2 doses; systematic dose-response characterization across endpoint types would strengthen the literature.

4. Independence from Khavinson laboratory — Much of the Epithalon literature originates from a small number of Russian laboratories. Independent replication in Western research institutions remains limited.

5. Mechanisms of telomere effects — Whether Epithalon acts directly on TERT gene expression, post-translational TERT modification, or through indirect pathways remains an open question.

---

Internal Links for Researchers

• •Epithalon Research Guide: Longevity Research Context
• •GHK-Cu vs Epithalon: Anti-Aging Research Comparison
• •Skin & Collagen Peptide Stack: GHK-Cu + Epithalon
• •Sleep & Recovery Peptide Stack: Epithalon + DSIP
• •Peptide Storage Best Practices
• •Research Peptide Equipment Guide
• •Peptide Degradation and Storage Science

---

Summary

Epithalon (Ala-Glu-Asp-Gly) represents one of the most extensively published synthetic peptide bioregulators in the gerontological research literature, with the majority of published studies emerging from Khavinson's laboratory in St. Petersburg over three decades. The research program has established a consistent body of preclinical evidence for:

• •Lifespan extension in rodent models with cyclic subcutaneous administration
• •Melatonin rhythm restoration in aged rodents
• •Reduced tumor incidence in cancer-prone strains
• •Retinal and neurological cytoprotection in aging models

For researchers establishing an Epithalon protocol, the key practical parameters are:

• •Reconstitute with bacteriostatic water at 1 mg/mL (SC injection) or sterile PBS/water for cell culture
• •Store reconstituted solutions at 2–8°C for up to 28 days, protected from light
• •Use cyclic dosing (5 days on, 25–30 days off) for long-term in vivo studies
• •Subcutaneous injection is the best-characterized in vivo route
• •In vitro concentrations of 0.1–100 ng/mL are appropriate for cell biology studies

The primary research opportunity is independent replication and mechanistic characterization of Epithalon's telomere effects in well-characterized human cell systems, using modern molecular biology techniques.

For research purposes only. Not for human use. Epithalon has not been approved by the FDA or any regulatory authority for human therapeutic or clinical use.